| Outcome Measures: |
Primary: Cmax, Peak Plasma Concentration (Cmax) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level, 22 days|AUC0-t, Area under the plasma concentration versus time curve (AUC0-t)) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level, 22 days|AUC0-∞, Area under the plasma concentration versus time curve (AUC0-∞)) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level, 22 days | Secondary: Tmax, Peak Time （Tmax）of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level, 22 days|T1/2z, Half time （T1/2z）of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level, 22 days|CLz/F, Clearance (Clz/F)of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level, 22 days
|
